特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
372673

骨髄移植拒絶反応:パイプライン製品の分析

Bone Marrow Transplant Rejection - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 797 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
骨髄移植拒絶反応:パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 797 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

骨髄移植拒絶反応は、幹細胞または骨髄移植の後起こることのある合併症です。新しく移植されたドナー細胞は、移植レシピエントの体を攻撃します。徴候は、胸痛、悪寒、血圧低下、熱、顔面紅潮、味覚異常、頭痛、蕁麻疹、吐き気、疼痛、息切れなどです。治療には免疫抑制薬を用います。

当レポートでは、骨髄移植拒絶反応に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

骨髄移植拒絶反応 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/研究機関で研究中の製品

治療薬開発に従事している企業

  • AbbVie Inc
  • AbGenomics International, Inc.
  • Actelion Ltd
  • Alexion Pharmaceuticals Inc
  • Amunix Operating Inc.
  • Apceth GmbH & Co. KG
  • arGEN-X BV
  • Athersys, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Cancer Treatment International Limited
  • Biogen Inc
  • Boryung Pharmaceutical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cantex Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • Cell Source, Inc.
  • Cell2B S.A.
  • CellECT Bio, Inc.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Cynata Therapeutics Limited
  • Cytodyn Inc.
  • Dompe Farmaceutici S.p.A.
  • Dr. Falk Pharma GmbH
  • Escape Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • Generon (Shanghai) Corporation Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmuNext, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Kadmon Corporation, LLC
  • Kamada Ltd.
  • Kiadis Pharma N.V.
  • Kymab Limited
  • キョーリン製薬
  • MacroGenics, Inc.
  • Mallinckrodt Plc
  • Medsenic
  • Mesoblast Limited
  • Millennium Pharmaceuticals Inc
  • Neopharm Ltd.
  • Nohla Therapeutics Inc.
  • Novartis AG
  • OncoImmune, Inc.
  • OSE Immunotherapeutics
  • Pharmicell Co., Ltd.
  • Pluristem Therapeutics Inc.
  • REGiMMUNE Corporation
  • Rigel Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Seattle Genetics, Inc.
  • Seres Therapeutics, Inc.
  • Sigmoid Pharma Limited
  • Spherium Biomed S.L.
  • Taiga Biotechnologies, Inc.
  • 武田薬品工業
  • Targazyme, Inc.
  • Therapix Biosciences Ltd
  • Tobira Therapeutics, Inc.
  • Vault Pharma Inc.
  • Xenikos B.V.
  • ZIOPHARM ONCOLOGY, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Bone Marrow Transplant Rejection, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by Adienne Pharma & Biotech, H2 2020
  • Bone Marrow Transplant Rejection - Pipeline by AltruBio Inc, H2 2020
  • Bone Marrow Transplant Rejection - Dormant Projects, H2 2020
  • Bone Marrow Transplant Rejection - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Bone Marrow Transplant Rejection, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
目次
Product Code: GMDHC12475IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2020, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 11, 38, 17, 3, 44, 7 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Bone Marrow Transplant Rejection - Overview
  • Bone Marrow Transplant Rejection - Therapeutics Development
  • Bone Marrow Transplant Rejection - Therapeutics Assessment
  • Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
  • Bone Marrow Transplant Rejection - Drug Profiles
  • Bone Marrow Transplant Rejection - Dormant Projects
  • Bone Marrow Transplant Rejection - Discontinued Products
  • Bone Marrow Transplant Rejection - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.